Table 1.

Vaccine experiment details.

Experiment	Groups	Vaccine Prime	Prime-boost interval	Vaccine Boost	3 days pre-challenge samples	Boost-challenge interval	Aerosol challenge* dose	Streptomycin **	3 days post-challenge samples***
A	Male	PBS (sham)	21 d	PBS (sham)	nd	31 d	1.1 x 105	nd	n=6
	Male	Combo ΔyscN		Combo ΔyscN	nd		1.1 x 105	nd	n=6
	Male	Combo ΔyscN		rF1-V****	nd		1.1 x 105	nd	n=6
B	Female	PBS (sham)	21 d	PBS (sham)	n=4	28 d	4.7 x 105	nd	n=4
	Male	PBS (sham)		PBS (sham)	n=4		5.7 x 105	nd	n=4
	Female	rF1-V		Δcaf1	n=4		4.7 x 105	nd	n=3
	Male	rF1-V		Δcaf1	n=4		5.7 x 105	nd	n=4
	Female	Δcaf1		rF1-V	n=3		4.7 x 105	nd	n=3
	Male	Δcaf1		rF1-V	n=4		5.7 x 105	nd	n=4
C	Female	PBS (sham)	21 d	PBS (sham)	n=4	29 d	2.0 x 105	nd	n=4
	Male	PBS (sham)		PBS (sham)	n=4		2.4 x 105	nd	n=4
	Female	rF1-V		ΔyopD/Δcaf1	n=4		2.0 x 105	nd	n=4
	Male	rF1-V		ΔyopD/Δcaf1	n=4		2.4 x 105	nd	n=4
	Female	ΔyopD/Δcaf1		rF1-V	n=4		2.0 x 105	nd	n=4
	Male	ΔyopD/Δcaf1		rF1-V	n=4		2.4 x 105	nd	n=4
D	Female	PBS (sham)	28 d	PBS (sham)	nd	28 d	6.7 x 105	nd	nd
	Male	PBS (sham)		PBS (sham)	nd		7.7 x 105	nd	nd
	Female	PBS (sham)		PBS (sham)	nd		6.7 x 105	20 mg/kg	nd
	Male	PBS (sham)		PBS (sham)	nd		7.7 x 105	20 mg/kg	nd
	Female	rF1-V		Δcaf1	nd		6.7 x 105	nd	nd
	Male	rF1-V		Δcaf1	nd		7.7 x 105	nd	nd
	Female	Δcaf1		rF1-V	nd		6.7 x 105	nd	nd
	Male	Δcaf1		rF1-V	nd		7.7 x 105	nd	nd
	Female	Δcaf1		rF1-V	nd		6.7 x 105	20 mg/kg	nd
	Male	Δcaf1		rF1-V	nd		7.7 x 105	20 mg/kg	nd
	Female	ΔyopD/Δcaf1		rF1-V	nd		6.7 x 105	nd	nd
	Male	ΔyopD/Δcaf1		rF1-V	nd		7.7 x 105	nd	nd
	Female	ΔyopD/Δcaf1		rF1-V	nd		6.7 x 105	20 mg/kg	nd
	Male	ΔyopD/Δcaf1		rF1-V	nd		7.7 x 105	20 mg/kg	nd

*After challenge, in all cases mice were followed for 21 days to assess survival, with n=10 in all groups except where indicated.

**Every 6 hours, starting 60 hours post-challenge.

***In Experiments A-C, in addition to the mice followed for survival, a separate group of mice were euthanized for assessment at 3 dpi.

****In all cases, rF1-V indicates 2 µg rF1-V complexed with CpG and Alhydrogel.